Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free POLB Stock Alerts

Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma logo
GBX 6.75 -0.08 (-1.10%)
As of 06/29/2026 12:28 PM Eastern
Compare

POLB vs. BTG, ARIX, CIR, TILS, and VSN

Should you buy Poolbeg Pharma stock or one of its competitors? MarketBeat compares Poolbeg Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Poolbeg Pharma include BTG (BTG), Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to BTG?

BTG (LON:BTG) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

In the previous week, BTG had 3 more articles in the media than Poolbeg Pharma. MarketBeat recorded 3 mentions for BTG and 0 mentions for Poolbeg Pharma. BTG's average media sentiment score of 0.19 beat Poolbeg Pharma's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company Overall Sentiment
BTG Neutral
Poolbeg Pharma Neutral

BTG's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BTGN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

BTG has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£159.40M1.19N/A£6.0019.67
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

BTG currently has a consensus price target of GBX 160, suggesting a potential upside of 35.59%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Poolbeg Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Poolbeg Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

19.7% of BTG shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 19.7% of BTG shares are held by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BTG beats Poolbeg Pharma on 12 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Arix Bioscience?

Poolbeg Pharma (LON:POLB) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Arix Bioscience 105.64%6.41%2.18%

Poolbeg Pharma has a beta of 1.821, meaning that its share price is 82% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Arix Bioscience Neutral

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 10 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Circassia Group (LON:CIR) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Poolbeg Pharma Neutral

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for Poolbeg Pharma. Tiziana Life Sciences' average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Poolbeg Pharma Neutral

Summary

Tiziana Life Sciences and Poolbeg Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Verseon (LON:VSN) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

In the previous week, Verseon's average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company Overall Sentiment
Verseon Neutral
Poolbeg Pharma Neutral

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

Summary

Verseon and Poolbeg Pharma tied by winning 3 of the 6 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

POLB vs. The Competition

Export
MetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£47.60M£508.45M£6.85B£2.78B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-7.183.1126.04366.54
Price / SalesN/A6,785.72550.3985,951.69
Price / Cash2.1113.1329.0927.87
Price / Book0.0089.3710.987.75
Net Income-£4.50B-£96.07M£3.57B£5.89B
7 Day Performance-7.53%1.23%3.06%-1.01%
1 Month Performance15.38%-0.19%0.72%-1.74%
1 Year Performance103.50%74.49%36.82%65.54%

Poolbeg Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
N/AGBX 6.75
-1.1%		N/A+103.5%£47.60MN/AN/A12
BTG
BTG
4.3395 of 5 stars		GBX 117.50
-1.3%		GBX 160
+36.2%		N/A£189.30M£159.40M19.584,690
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel